Literature DB >> 12970870

Using yeast two-hybrid system to identify ECRG2 associated proteins and their possible interactions with ECRG2 gene.

Yong-Ping Cui1, Jian-Bo Wang, Xin-Yu Zhang, Mei-Xia Bi, Li-Ping Guo, Shih-Hsin Lu.   

Abstract

AIM: To identify esophageal cancer related gene2 (ECRG2) associated proteins and their possible interactions with ECRG2 gene.
METHODS: In the yeast forward two-hybrid system, ECRG2 was fused with the DNA-binding domain (DBD) of Gal4 and human fetal liver cDNA library was fused with the transcriptional activation domain (AD) of Gal4. We performed a high-stringency scale procedure to screen ECRG2 against human fetal liver cDNA library and characterized positives by sequence analysis.
RESULTS: We found the following 9 putatively associated proteins. They were metallothionein2A, metallothionein1H, metallothionein1G, ferritin, erythrocyte membrane protein band4.2, mitochondrial ribosomal protein S12, hypothetical protein FLJ10101, and a novel gene whose cDNA was found to have no strong homology to any other previously characterized gene whose DDBJ/EMBL/GenBank accession number is AF422192 mapped to human chromosome 14q31.
CONCLUSION: MT, a potential interaction partner for ECRG2, might be involved in the regulation of cell proliferation and apoptosis, and in various physiological processes. Determination of a reliability score for each single protein-protein interaction, especially interaction of ECRG2 and MT, permits the assignment of ECRG2 and unannotated proteins to biological pathways. A further understanding of the association between ECRG2 and MT should facilitate the functions of ECRG2 gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970870      PMCID: PMC4656638          DOI: 10.3748/wjg.v9.i9.1892

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  Alterations of oncogenes and tumor suppressor genes in esophageal cancer in China.

Authors:  S H Lu
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

Review 2.  Proteomics: a new approach to the study of disease.

Authors:  G Chambers; L Lawrie; P Cash; G I Murray
Journal:  J Pathol       Date:  2000-11       Impact factor: 7.996

3.  Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.

Authors:  Y Tan; R Sinniah; B H Bay; G Singh
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

Review 4.  Significance of metallothionein overexpression in human tumours.

Authors:  B Jasani; K W Schmid
Journal:  Histopathology       Date:  1997-09       Impact factor: 5.087

5.  Expression of metallothionein in colorectal cancers and synchronous liver metastases.

Authors:  Y Hishikawa; H Kohno; S Ueda; T Kimoto; D K Dhar; H Kubota; M Tachibana; T Koji; N Nagasue
Journal:  Oncology       Date:  2001       Impact factor: 2.935

6.  [Cloning and identification of cDNA fragments related to human esophageal cancer].

Authors:  T Su; H Liu; S Lu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1998-07

7.  Immunohistochemical metallothionein expression in thymoma: correlation with histological types and cellular origin.

Authors:  T Kuo; S K Lo
Journal:  Histopathology       Date:  1997-03       Impact factor: 5.087

8.  Significant overexpression of metallothionein and cyclin D1 and apoptosis in the early process of rat urinary bladder carcinogenesis induced by treatment with N-butyl-N-(4-hydroxybutyl)nitrosamine or sodium L-ascorbate.

Authors:  K Takaba; K Saeki; K Suzuki; H Wanibuchi; S Fukushima
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

9.  Metallothionein expression in hepatocellular carcinoma.

Authors:  Geng-Wen Huang; Lian-Yue Yang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

10.  Gene expression profiles at different stages of human esophageal squamous cell carcinoma.

Authors:  Jin Zhou; Li-Qun Zhao; Mo-Miao Xiong; Xiu-Qin Wang; Guan-Rui Yang; Zong-Liang Qiu; Min Wu; Zhi-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

View more
  3 in total

1.  ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA.

Authors:  Xin-Fang Hou; Lin-Ping Xu; Hai-Yan Song; Shuai Li; Chen Wu; Ju-Feng Wang
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

Review 2.  SPINKs in Tumors: Potential Therapeutic Targets.

Authors:  Chengcheng Liao; Qian Wang; Jiaxing An; Minglin Zhang; Jie Chen; Xiaolan Li; Linlin Xiao; Jiajia Wang; Qian Long; Jianguo Liu; Xiaoyan Guan
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

3.  RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts.

Authors:  Xuefeng Zhang; Jussara Hagen; Viviane P Muniz; Tarik Smith; Gary S Coombs; Christine M Eischen; Duncan I Mackie; David L Roman; Richard Van Rheeden; Benjamin Darbro; Van S Tompkins; Dawn E Quelle
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.